RU2007148266A - Комбинированная терапия с использованием соединения диарилмочевины и ингибиторов pi3, akt-киназы или mtor (рапамицины) для лечения рака - Google Patents
Комбинированная терапия с использованием соединения диарилмочевины и ингибиторов pi3, akt-киназы или mtor (рапамицины) для лечения рака Download PDFInfo
- Publication number
- RU2007148266A RU2007148266A RU2007148266/15A RU2007148266A RU2007148266A RU 2007148266 A RU2007148266 A RU 2007148266A RU 2007148266/15 A RU2007148266/15 A RU 2007148266/15A RU 2007148266 A RU2007148266 A RU 2007148266A RU 2007148266 A RU2007148266 A RU 2007148266A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- wortmannin
- alkyl
- combination according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 24
- 239000003112 inhibitor Substances 0.000 title claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 4
- 101150097381 Mtor gene Proteins 0.000 title 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 title 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical compound C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 title 1
- -1 hydrate Substances 0.000 claims abstract 17
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Chemical class COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 11
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Chemical class COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract 7
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract 7
- 229960002930 sirolimus Drugs 0.000 claims abstract 7
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical class C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims abstract 6
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 4
- 239000002207 metabolite Substances 0.000 claims abstract 3
- 239000000651 prodrug Substances 0.000 claims abstract 3
- 229940002612 prodrug Drugs 0.000 claims abstract 3
- 230000019491 signal transduction Effects 0.000 claims abstract 3
- 239000012453 solvate Substances 0.000 claims abstract 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims abstract 2
- UCOYIUOEXIYJFD-UHFFFAOYSA-N 2-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1N1C(C=2C=C3C(C4=CC=CC=C4C=C3)=CC=2)=CC(C(F)(F)F)=N1 UCOYIUOEXIYJFD-UHFFFAOYSA-N 0.000 claims abstract 2
- YULUCECVQOCQFQ-UHFFFAOYSA-N OSU-03012 Chemical compound C1=CC(NC(=O)CN)=CC=C1N1C(C=2C=C3C(C4=CC=CC=C4C=C3)=CC=2)=CC(C(F)(F)F)=N1 YULUCECVQOCQFQ-UHFFFAOYSA-N 0.000 claims abstract 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims abstract 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims abstract 2
- GJZGRYXGQBWBEB-AVMFAVRISA-N [(2r)-2-methoxy-3-octadecoxypropyl] [(1r,2r,3s,4r,6r)-2,3,4,6-tetrahydroxycyclohexyl] hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP(O)(=O)O[C@@H]1[C@H](O)C[C@@H](O)[C@H](O)[C@H]1O GJZGRYXGQBWBEB-AVMFAVRISA-N 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims abstract 2
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960000590 celecoxib Drugs 0.000 claims abstract 2
- 239000003623 enhancer Substances 0.000 claims abstract 2
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 2
- 125000005842 heteroatom Chemical group 0.000 claims abstract 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract 2
- 229960000367 inositol Drugs 0.000 claims abstract 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229960001302 ridaforolimus Drugs 0.000 claims 1
- QFMKPDZCOKCBAQ-NFCVMBANSA-N sar943-nxa Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)CC1 QFMKPDZCOKCBAQ-NFCVMBANSA-N 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05011477 | 2005-05-27 | ||
| EP05011477.6 | 2005-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007148266A true RU2007148266A (ru) | 2009-07-10 |
Family
ID=36636325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007148266/15A RU2007148266A (ru) | 2005-05-27 | 2006-05-13 | Комбинированная терапия с использованием соединения диарилмочевины и ингибиторов pi3, akt-киназы или mtor (рапамицины) для лечения рака |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1888067A1 (enExample) |
| JP (1) | JP2008542214A (enExample) |
| KR (1) | KR20080018908A (enExample) |
| CN (1) | CN101257903A (enExample) |
| AU (1) | AU2006251429A1 (enExample) |
| BR (1) | BRPI0610048A2 (enExample) |
| CA (1) | CA2609389A1 (enExample) |
| IL (1) | IL187508A0 (enExample) |
| MX (1) | MX2007014726A (enExample) |
| RU (1) | RU2007148266A (enExample) |
| WO (1) | WO2006125540A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| DE602006017188D1 (de) | 2005-03-07 | 2010-11-11 | Bayer Schering Pharma Ag | Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
| CA2633400A1 (en) * | 2005-12-15 | 2007-06-21 | Bayer Healthcare Ag | Diaryl urea for treating virus infections |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| US20100173954A1 (en) * | 2007-01-19 | 2010-07-08 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
| ES2429107T3 (es) * | 2007-01-19 | 2013-11-13 | Bayer Healthcare Llc | Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT |
| US7947723B2 (en) | 2008-02-01 | 2011-05-24 | Spelman College | Synthesis and anti-proliferative effect of benzimidazole derivatives |
| CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| WO2009156070A1 (en) * | 2008-06-25 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Diaryl urea for treating heart failure |
| US8791131B2 (en) * | 2008-09-30 | 2014-07-29 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
| EP2435040A2 (en) | 2009-05-28 | 2012-04-04 | President and Fellows of Harvard College | N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| CN102775385A (zh) * | 2011-05-10 | 2012-11-14 | 湖南有色凯铂生物药业有限公司 | N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用 |
| CN102885814A (zh) * | 2012-01-17 | 2013-01-23 | 湖南有色凯铂生物药业有限公司 | 一种化合物及其作为抗癌药物的应用 |
| CN102643229A (zh) * | 2012-01-17 | 2012-08-22 | 湖南有色凯铂生物药业有限公司 | N-((4-氯-3-三氟甲基)苯基)-n’-((2-氟-4-(2-氨基甲酰基)-4-吡啶基氧)苯基)脲及其作为抗癌药物的应用 |
| CN102940884B (zh) * | 2012-11-19 | 2013-11-06 | 上海市肿瘤研究所 | 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用 |
| US10420761B2 (en) | 2013-03-15 | 2019-09-24 | University Of Florida Research Foundation, Inc. | Allosteric inhibitors of thymidylate synthase |
| HUE055928T2 (hu) * | 2014-12-17 | 2022-01-28 | Pfizer | PI3K/MTOR-inhibitorok készítményei intravénás adagolásra |
| CN104892632B (zh) * | 2015-06-03 | 2017-12-26 | 道中道（菏泽）制药有限公司 | 一种晶体形式的依维莫司及其制备方法 |
| US10835524B2 (en) | 2015-06-24 | 2020-11-17 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of pancreatic cancer and uses thereof |
| CN104906086A (zh) * | 2015-06-24 | 2015-09-16 | 安徽四正医药科技有限公司 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物用于治疗肾小球肾炎药物的应用 |
| KR102544163B1 (ko) * | 2022-08-10 | 2023-06-16 | 주식회사 하이밸 | 소음저감형 유량 및 압력 조절용 감압밸브 |
| CN115804844B (zh) * | 2022-09-26 | 2024-05-10 | 郑州大学 | 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1663978T3 (pl) * | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
-
2006
- 2006-05-13 AU AU2006251429A patent/AU2006251429A1/en not_active Abandoned
- 2006-05-13 KR KR1020077030272A patent/KR20080018908A/ko not_active Withdrawn
- 2006-05-13 EP EP06724813A patent/EP1888067A1/en not_active Withdrawn
- 2006-05-13 RU RU2007148266/15A patent/RU2007148266A/ru not_active Application Discontinuation
- 2006-05-13 CA CA002609389A patent/CA2609389A1/en not_active Abandoned
- 2006-05-13 BR BRPI0610048-1A patent/BRPI0610048A2/pt not_active Application Discontinuation
- 2006-05-13 CN CNA2006800185177A patent/CN101257903A/zh active Pending
- 2006-05-13 WO PCT/EP2006/004524 patent/WO2006125540A1/en not_active Ceased
- 2006-05-13 JP JP2008512730A patent/JP2008542214A/ja active Pending
- 2006-05-13 MX MX2007014726A patent/MX2007014726A/es not_active Application Discontinuation
-
2007
- 2007-11-20 IL IL187508A patent/IL187508A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0610048A2 (pt) | 2010-05-25 |
| MX2007014726A (es) | 2008-02-14 |
| IL187508A0 (en) | 2008-06-05 |
| CA2609389A1 (en) | 2006-11-30 |
| CN101257903A (zh) | 2008-09-03 |
| WO2006125540A1 (en) | 2006-11-30 |
| JP2008542214A (ja) | 2008-11-27 |
| KR20080018908A (ko) | 2008-02-28 |
| EP1888067A1 (en) | 2008-02-20 |
| AU2006251429A1 (en) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008542214A5 (enExample) | ||
| EP2370076B1 (en) | Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor | |
| US20180133226A1 (en) | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor | |
| JP2008545670A5 (enExample) | ||
| MY189118A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | |
| WO2012030685A3 (en) | Indazole derivatives useful as erk inhibitors | |
| NO20082101L (no) | Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer | |
| WO2011113802A3 (en) | Imidazopyridine and purine compounds, compositions and methods of use | |
| CA2904338A1 (en) | Use of imidazole derivatives in combination with a braf inhibitor or mek inhibitor in the treatment of cancer | |
| JP2014505660A5 (enExample) | ||
| US20020183239A1 (en) | Antineoplastic combinations | |
| AU2008202690A1 (en) | Antineoplastic combination | |
| RU2008119435A (ru) | Производные триазолопиридина в качестве ингибиторов липаз и фосфолипаз | |
| KR20080018908A (ko) | 암 치료용 디아릴 우레아 화합물 및 ｐｉ３, ａｋｔ 키나제또는 ｍｔｏｒ 억제제 (라파마이신)를 포함하는 병용요법 | |
| US20130178479A1 (en) | Pharmaceutical combinations | |
| De Pascale et al. | Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor | |
| AU2002259309A1 (en) | Antineoplastic combinations | |
| WO2009009531A3 (en) | Pyrimidinecarboxamide derivatives for the treatment of hiv infections | |
| KR20130092412A (ko) | 유기 화합물의 조합물 | |
| WO2006016067A3 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer | |
| MX2021005892A (es) | Novedosos activadores de guanilato ciclasa soluble e inhibidores de fosfodiesterasa con modo de accion dual y usos de estos. | |
| Rowinsky | Preclinical and clinical development of Exatecan (DX-951f) A hexacyclic camptothecin analog | |
| Staben et al. | Structure-based optimization of pyrazolo-pyrimidine and-pyridine inhibitors of PI3-kinase | |
| EP2382979A3 (en) | Use of core 2 GlcNac-T inhibitors III for treating autoimmune diseases | |
| RU2007148268A (ru) | Комбинированная терапия с использованием диарилмочевины для лечения заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20090616 |